Our Financial Highlights for 2019
2019 saw continued strong growth and cash generation.
Continued strong performance from our International Star and other consumer brands, led by KELO-COTE™.
International sales saw another year of strong growth.
Results include the first full year’s revenues from NizoralTM (under Johnson & Johnson management); good progress made with the Nizoral transition and enhancement of our Asia Pacific operations.
Continued strong cash generation, with leverage now below 1.5x
To view in detail click here to download our 2019 Annual Report.
Please view our five year financial summary below
|Year ended 31 December 2015 £m||Year ended 31 December 2016 £m||Year ended 31 December 2017 £m||Year ended 31 December 2018 £m||Year ended 31 December 2019 £m|
|Operating profit before non-underlying items||10.6||25.6||25.8||28.9||37.4|
|Non-underlying operating items||(6.3)||-||4.4||(5.3)||(1.8)|
|Profit before tax before non-underlying items||11.0||22.2||23.9||28.1||32.9|
|Profit before tax after non-underlying items||15.2||22.2||28.3||22.8||31.1|
|Average shares in issue (millions)||272.7||469.4||473.8||497.2||520.7|
|Shares in issue at period end (millions)||468.2||472.6||475.0||518.2||529.4|
|Earnings per share – basic (p)||4.65||3.85||6.08||3.69||4.80|
|Earnings per share – adjusted underlying basic (p)||3.69||3.69||4.05||4.54||5.09|
* Non-IFRS alternative performance measures (see note 34). See-through revenue includes sales from Nizoral as if they had been invoiced by Alliance. For statutory accounting purposes the product margin on Nizoral sales is included within Revenue, in line with IFRS 15
** The 2017 measure refers to the Underlying Adjusted Basic EPS as disclosed in the 2017 Annual Report which was adjusted to normalise the impact of significant changes in overseas tax rates.